Form 8-K - Current report:
SEC Accession No. 0001558370-23-004698
Filing Date
2023-03-27
Accepted
2023-03-27 16:01:23
Documents
14
Period of Report
2023-03-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20230323x8k.htm   iXBRL 8-K 41045
2 EX-10.1 acrs-20230323xex10d1.htm EX-10.1 19672
  Complete submission text file 0001558370-23-004698.txt   272643

Data Files

Seq Description Document Type Size
3 EX-101.SCH acrs-20230323.xsd EX-101.SCH 3253
4 EX-101.LAB acrs-20230323_lab.xml EX-101.LAB 632
5 EX-101.PRE acrs-20230323_pre.xml EX-101.PRE 10569
8 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20230323x8k_htm.xml XML 4840
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 23764496
SIC: 2834 Pharmaceutical Preparations